<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00153998</url>
  </required_header>
  <id_info>
    <org_study_id>CELIM</org_study_id>
    <nct_id>NCT00153998</nct_id>
  </id_info>
  <brief_title>Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)</brief_title>
  <official_title>Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      General Objectives:

        -  To test the feasibility of neoadjuvant treatment with cetuximab/chemotherapy followed by
           liver resection

        -  To determine the optimal combination (cetuximab/FOLFOX versus cetuximab/FOLFIRI) for
           further trials in preoperative chemotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with liver metastasis will be screened for this study. Eligible patients will
      complete the pretreatment evaluation including an abdominal CT scan that will be presented to
      the local surgeon and the radiologist for proving of resectability of hepatic lesions.
      Additionally, CT scans will be reviewed by three reference surgeons. In case of
      non-resectability, as defined above, CT- or ultrasound- guided biopsy of one of the liver
      metastases will be performed, unless biopsy material is available from prior biopsy of one of
      the liver metastases.

      Instead of an ultrasound-guided biopsy, a CT-guided biopsy may be performed.

      Formalin-fixed, paraffin embedded metastatic tissue will be sent to reference laboratory
      (Prof. Störkel, Wuppertal) for immunohistochemical analysis of EGFR- expression.

      Additionally tissue will be stored in &quot;RNA later&quot; for gene expression analysis if agreed by
      the patient.

      Additionally, the primary tumor will be collected and sent to the reference laboratory for
      analysis of EGFR- expression (if agreement of the patient exists).

      Patients will be randomized to a combination of:

      Cetuximab/FOLFIRI (irinotecan/5-FU/FA) or Cetuximab/FOLFOX6 (oxaliplatin/5-FU/FA)

      All patients receive a four month treatment (eight cycles) of the allocated treatment.

      Resection is planned after completion of neoadjuvant treatment and should be performed
      between 4 and 6 weeks after the last dose of chemotherapy. Probes of the resected material
      (in liquid nitrogen and paraffin embedded material will be collected).

      If a resection is not possible after eight administrations of chemotherapy, chemotherapy will
      be continued until tumor progression (maximal duration of treatment 2 years) and the patient
      will be evaluated for a potential resection every two months.

      After resection, postoperative treatment is planned for 3 months (6 cycles). Treatment start
      is planned between 4 and 8 weeks after the operation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response, defined as partial and complete response according to RECIST (Response Evaluation Criteria in Solid Tumors) - criteria in the intention-to-treat [ITT-] population</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of R0 liver resection (ITT- population)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (ITT- population)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival after resection (ITT- population)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (ITT- population)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (all patients that received any study drug)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular predictive markers for response and toxicity</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cetuximab and FOLFIRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cetuximab and FOLFOX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver resection</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab and FOLFIRI</intervention_name>
    <description>Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:
Cetuximab 250 mg/m² (1.0 h i.v.) weekly
Irinotecan 180 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cetuximab(C225, Erbitux®, Merck KGaA)</other_name>
    <other_name>Irinotecan (irinotecan HCl, CPT-11 or Campto®, Aventis)</other_name>
    <other_name>5-Fluorouracil (5-FU)</other_name>
    <other_name>Folinic acid (FA, i.e. Leucovorin®, Wyeth)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab and FOLFOX</intervention_name>
    <description>Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:
Cetuximab 250 mg/m² (1.0 h i.v.) weekly
Oxaliplatin 100 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Cetuximab(C225, Erbitux®, Merck KGaA)</other_name>
    <other_name>Oxaliplatin (L-OHP, Eloxatin®, Sanofi-Synthelabo)</other_name>
    <other_name>5-Fluorouracil (5-FU)</other_name>
    <other_name>Folinic acid (FA, i.e. Leucovorin®, Wyeth)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with non-resectable, histologically confirmed, synchronous or metachronous
             colorectal liver metastases. Patients with non-resectable metastases are defined as;
             patients with five or more liver metastases; and/or patients with liver metastases
             that are technically non-resectable (local surgeon in cooperation with local
             radiologist will define non-resectability on the basis of remaining functional liver
             tissue, infiltration of all liver veins, infiltration of both liver arteries, both
             portal branches or both bile ducts).

          -  Patients with simultaneous liver metastases are eligible, if the primary tumor has
             been resected at least 1 month prior to chemotherapy.

          -  Karnofsky Performance Status ≥ 80

          -  Informed consent

          -  Adequate bone marrow function, liver and renal function (neutrophils &gt; 1.5 x 10^9/l;
             thrombocytes &gt; 100 x 10^9/l; hemoglobin &gt; 8.0 g/l; bilirubin ≤ 1.5 x upper limit of
             normal [ULN] and not increasing more than 25% within the last 4 weeks; ALAT and ASAT &lt;
             5 x UNL; serum creatinine ≤ 1.5 x UNL)

          -  Age ≥ 18 years

        Exclusion Criteria:

          -  Any evidence of extrahepatic metastases, lymph node metastases and primary tumor
             recurrence

          -  Prior chemotherapy (except adjuvant chemotherapy with an interval of ≥ 6 months)

          -  Previous exposure to EGFR (epidermal growth factor receptor)-targeting therapy

          -  Radiotherapy or major abdominal or thoracic surgery (excluding diagnostic biopsy or
             port implantation) ≤ 4 weeks before study entry

          -  Concurrent systemic immune therapy, chemotherapy, or hormone therapy

          -  Investigational agents or participation in clinical trials within 30 days before start
             of the treatment in study

          -  Clinically relevant coronary disease or myocardial infarction within 12 months before
             study entry

          -  Peripheral neuropathy &gt; CTC grade I

          -  Inflammatory bowel disease

          -  Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin
             or pre-invasive carcinoma of the cervix with adequate treatment)

          -  History of severe psychiatric illness

          -  Drug or alcohol abuse

          -  Breast feeding or pregnant women, no effective contraception if risk of conception
             exists (male and female patients)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus-Henning Köhne, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Oldenburg GmbH, Dr.-Eden-Str.10; 26133 Oldenburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gunnar Folprecht, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Dresden, Fetscherstr. 74, 01307 Dresden, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universitaet Wien, Universitaetsklinik für Chirurgie</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Aschersleben</name>
      <address>
        <city>Aschersleben</city>
        <zip>06449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite-Campus Benjamin Franklin, Innere Medizin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite-Campus, Virchow-Klinikum, Innere Medizin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Celle</name>
      <address>
        <city>Celle</city>
        <zip>29223</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital &quot;Carl Gustav Carus&quot;</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florence-Nightingale-Krankenhaus</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40489</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Erlangen-Nuernberg, Chirurgie</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westdeutsches Tumorzentrum, Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe Universitaet, Chirurgie</name>
      <address>
        <city>Frankfurt Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum GmbH Innere Medizin I</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKSH Campus Kiel, II. Medizinische Klinik</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Magdeburg-Olvenstedt</name>
      <address>
        <city>Magdeburg</city>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Mannheim gGmbH, III. Medizinische Klinik</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Grosshadern, III. Medizinische Klinik</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg GmbH</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Passau, II. Medizinische Klinik</name>
      <address>
        <city>Passau</city>
        <zip>94032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Hansestadt Stralsund GmbH, Medizinische Klinik</name>
      <address>
        <city>Stralsund</city>
        <zip>18435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brueder Trier, Chirurgie</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Wuerzburg, Chirurgie</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>February 26, 2009</last_update_submitted>
  <last_update_submitted_qc>February 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Claus-Henning Köhne</name_title>
    <organization>now: Klinikum Oldenburg gGmbH</organization>
  </responsible_party>
  <keyword>Cetuximab</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>5-FU</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Resection</keyword>
  <keyword>Liver resection</keyword>
  <keyword>Neoadjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

